Based on the information mentioned above and considering that the impact of CYP2C19 polymorphisms on the long-term treatment response to ESC is not clear, we explored the association between CYP2C19 metabolizers and remission of depressive symptoms in a group of MDD patients receiving ESC for the long term (more than 3 years). The gene discussed is CYP2C19; the disease is major depressive disorder.